Background: We aimed to predict disease-free survival (DFS) in patients who failed to achieve a pathologic complete remission (pCR) after preoperative chemotherapy (PC).
introduction
Preoperative treatment is an established therapy for patients with operable breast cancer for whom a reduction of primary tumor size is required in order to allow breast conservation [1] [2] [3] .
Preoperative chemotherapy (PC) might be beneficial in several ways in addition to allowing breast conserving surgery in some of the patients. In fact, the degree of response to the primary treatment may be used as a prognostic marker. Several large randomized studies have shown that patients achieving a pathological complete remission (pCR) to chemotherapy have better long-term survival than those who respond incompletely to primary chemotherapy. Recent studies, however, indicated that pCR can be achieved in a minority of the patients. In particular, pCR rates range from 30% to 40% in those patients whose tumors do not express estrogen receptors (ERs) or progesterone receptors (PgRs), whereas in patients with endocrine responsive tumors pCR rates range between 2% and 10% [4] [5] [6] . Therefore, >75% of the patients currently fail to achieve a pCR and have an increased risk of relapse and death, even if they received additional systemic therapy.
Limited data are available on factors which are able to predict prognosis of breast cancer after PC in patients at substantial risk of relapse, although several models or nomograms were presented in the past based on both clinical and pathological features [7] [8] [9] .
We combined all pathological information available at surgery after PC in a nomogram which is able to calculate the overall probability of a specific clinical outcome for an individual patient. We subsequently validated the prognostic model, based on both categorical and continuous histological variables, to be used for the prediction of disease-free survival (DFS) for patients who received primary chemotherapy, resulted as incomplete responders, and had a homogeneous diagnostic and therapeutic environment. The first cohort included those patients treated with preoperative therapy at the European Institute of Oncology (EIO) (N = 577) and was used as a training set to develop the nomogram. pCRs were evaluated according to the criteria of Kuerer et al. [10] . In particular, the absence of invasive cancer on both the primary breast tumor and axillary lymph nodes qualified for pCR. Consequently, only those patients who presented invasive cancer on either the primary breast tumor and/or axillary lymph nodes were considered for the present study. Patients were treated with PC given in 3-week courses. Patients with partial remission or complete remission were candidates to receive a maximum of six courses. The regimens used during the conduct of the study included anthracycline-containing regimens, taxane-containing regimens and navelbine-containing regimens, as previously reported [4] .
patients and methods
The second cohort used as a validation set, included patients treated with PC in other institutions (N = 343) and that subsequently underwent surgery at the EIO.
Written informed consent was obtained from all patients. The study was notified to the Institutional Review Board.
pathology and immunohistochemistry
All patients had pathological evaluation carried out at the EIO. The original histological determinations, carried out before the patient was included in this analysis, were used. The histotype evaluation was carried out based on the results at final surgery.
Immunostaining experiments for the localization of ER and PgR, human epidermal growth factor receptor 2 (HER2) protein and Ki-67 antigen were carried out on consecutive tissue sections, as previously reported [4] . The following primary antibodies were used: the mAb to ER (Dako, Glostrup, Denmark; at 1/100 dilution), the mAb to PgR (Dako, 1/800), the MIB-1 mAb to the Ki-67 antigen (Immunotech, Marseille, France, 1/1200) and the polyclonal antiserum (Dako, 1/3200) to the HER2 protein.
The immunostained slides were evaluated independently by two of the authors. Only nuclear reactivity was taken into account for ER, PgR and Ki-67 antigen, whereas only an intense and complete membrane staining >10% of the tumor cells was taken as evidence of HER2/neu overexpression (3+).
statistical analysis
The main end point was DFS. DFS was defined as the length of time from the date of surgery to events such as relapse (including ipsilateral breast recurrence), appearance of a second primary cancer (including contralateral breast cancer) or death, whichever occurred first. For survivors, DFS was censored at the last follow-up visit. The DFS distribution was estimated using the Kaplan-Meier method, and log-rank test was used to test differences between survival distributions in the univariable analysis.
The Cox proportional hazard multivariable regression was used to build the nomogram for DFS, considering both categorical (histologic type, pT, lymphonodal status, HER2 status, vascular invasion, type of primary therapy and response to primary therapy) and continuous variables (age, ER, PgR and Ki-67) evaluated at surgery.
Departure from linearity in the relationship between continuous variables and DFS was evaluated by fitting restricted cubic spline models [11] . Schoenfeld residuals were used to check the adequacy of proportional hazard assumption [12] . Backward variable selection was used to determine variables significantly associated with the outcome. Variables with P value <0.10 were retained in the model.
The nomogram for DFS was created in the training cohort. Predictive accuracy of the nomogram was firstly assessed by internal validation, using bootstrap technique in order to reduce overfit bias [11] . It was evaluated with respect to discrimination (i.e. the ability of the model to classify a patient with the outcome from a patient without the outcome) and calibration (i.e. the agreement between the outcome frequencies observed in the data and the predicted probabilities of the model). Discrimination was measured by the Harrell's concordance statistics (c-index), which is the probability that given two randomly selected patients, the survival time predicted by the model is greater for the subject who survived longer. In case of analysis of censored data, the c-index is calculated using all possible pairs of patients at least one of whom has experienced the event. A value of 1 denotes perfect concordance, while a value of 0.5 is no better than chance. Calibration was evaluated by a visual inspection of the plot comparing the 5-year probabilities of event predicted by the model with the Kaplan-Meier 5-year survival proportions observed in groups defined by quantiles of predicted probabilities.
Finally, the nomogram was validated externally: for each patient of the validation cohort, the risk score of event was calculated using the parameter estimates from the model developed in the training cohort. Again, the 5-year predicted probabilities of event were compared with the observed, and the c-index was calculated.
All statistical analyses were carried out using the R software with the Design and Hmisc libraries [13] . All reported P values were two sided.
results Table 1 displays the characteristics at surgery of the 577 patients in the training cohort and the 343 patients in the validation cohort. The characteristics of the two cohorts did not differ greatly overall, except for type of primary therapy received. Six percent of the patients in the training cohort and 36% in the validation set received anthracyclines combined with taxanes, while additional hormonotherapy was given to 25% of the training cohort and only 4% of the validation cohort. A partial response was observed in the 62% and 57% of the training and validation cohort, respectively. The frequency of patients with more than three positive lymph nodes at surgery was greater in the validation (57%) than in the training (48%) cohort.
Forty-six percent and 43% of patients underwent breastconserving surgery in training and validation cohort, respectively. Radiotherapy was carried out in 74% of the patients in the training cohort and 77% in the validation sample. The majority of patients (93%) were candidate to adjuvant therapy both in training and validation cohort.
development of the model and internal validation
Among the 577 patients of the training cohort, median length of follow-up was 56 months (range 1-140). DFS at 5 years was 59% [95% confidence interval (CI) 55% to 64%] (Figure 1 ). Table 2 shows the univariate analysis of the factors measured at surgery. The factors that showed a statistically significant association with survival were type of primary therapy, histotype, residual tumour dimension (pT), number of positive lymph nodes, degree of tumour endocrine responsiveness, HER2 status, Ki-67 and peritumoral vascular invasion (PVI). When ER and PgR expression, Ki-67 and age were considered as continuous variables, no departure from linearity was observed in their relationship with survival.
In multivariable analysis, statistically significant prognostic/ predictive factors of DFS were residual tumour dimension (pT), number of positive lymph nodes, ER expression, HER2/ neu status, Ki-67 expression and PVI (Table 3 ). Figure 2 shows a nomogram to predict 5-year DFS, constructed on the basis of the fitted multivariable proportional hazard model. The nomogram is used by first determining the patient's score for each predictor. For example, an ER expression of 40% contributes approximately of 31 points; this is determined by comparing the location of the 40 value on the 'ER' axis to the 'Points' scale above and drawing a vertical line between the two axes. The scores for all considered predictors are determined in a similar manner and are summed to arrive at a Total Points value. This value is plotted on the Total Points axis. A vertical line drawn from the Total Points axis straight down to the 5-years DFS probability axis will indicate the patient's probability of remaining free from event for 5 years.
The bootstrap-corrected concordance index for the nomogram was 0.73 (95% CI 0.67-0.80) (discrimination). Figure 3A shows how the predictions from the model at 5 years compared with the actual survival probability for the patients in the training cohort, grouped into quintiles of the predicted risk score (calibration). The x-axis is the prediction calculated from the nomogram and the y-axis is the actual DFS observed in the cohort. Dashed line is the ideal relationship where model perfectly predict the actual outcome. The performance of our nomogram is plotted as the solid line that connects the dots. Calibration of our nomogram was good since it did not exhibit systematic over-or underprediction. Only for patients with intermediate prognosis, the model did not perform very well, with almost equal DFS observed probability (59% and 60%) in patients classified in the second and in the third quintile of predicted risk. The Xs indicate bootstrapcorrected estimates of the predicted DFS proportion. Vertical bars indicate 95% CI around the actual probability. Only for the second quintile of predicted risk, the model showed a significant overestimation of the risk of event within 5 years from the time of surgery (56% predicted versus 41% observed).
external validation
Patients in the validation cohort had worse survival compared with patients in the training set ( Figure 1 ). DFS at 5 years was 50% (95% CI 44% to 56%). The median length of follow-up was 50 months (range 1-127).
The discriminative ability and calibration of the nomogram was also evaluated in this cohort. The concordance index was 0.67 (95% CI 0.58-0.75), while predicted and observed 5-year DFS rates were fairly concordant ( Figure 3B ).
discussion
It has been assumed that pCR is a valid surrogate of long-term survival and cure from breast cancer. A large evidence from retrospective analyses of well-conducted clinical trials supports this notion [2, 3, 14, 15] . However, how to distinguish patients at high risk of relapse within those who failed to achieve a pCR remains uncertain. Appropriate identification of prognostic factors and factors predictive of responsiveness to specific adjuvant treatment programs after preoperative therapy continue to represent a major research issue. Intrinsically different subtypes of breast cancer were clearly recognized in the past years based on genetic profile and immunohistochemical demonstration of selected targets [16, 17] , but optimal tailoring of adjuvant therapies after PC is still a matter of debate. Treatment strategy should focus mainly on targeted therapies wherever possible, though acknowledging that supplementation with less target-specific chemotherapy is often required. This analysis provides useful insights into the treatment and prognosis of breast cancer because it is based on a large number of patients, collected in a relatively short time, thus allowing adoption of modern procedures. Other groups already developed nomograms based upon large number of subjects which are able to correlate patients' outcome after PC. However, data from past series include information on several aspects of the disease collected in the earlier period, when the various prognostic and predictive factors were not available in the fashion they are today [6] . Moreover, no central pathology review was carried out in some of these studies [7] .
In the present study, the surgeons, medical oncologists and most of all pathologists used consistent approaches during the years of reference. Adjuvant systemic therapies, besides an increased attention to precise determination of the biological characteristics of primary tumors, represent another relevant novelty between current and past assessments. Adjuvant treatment proposed was largely based on the degree of nodal involvement as well as on known prognostic features according to the recent St. Gallen Consensus Conference Guidelines [18] [19] [20] .
Here, we developed a nomogram which is able to predict DFS based upon expression of classical and newer pathologic characteristics of the primary tumor. Moreover, the degree of expression of selected features was used considering that the definition of arbitrary thresholds in a biological continuum might be misleading.
Among categorical variables, the nomogram included T stage, number of positive nodes, vascular invasion and HER2. The residual tumor size as well as the diameter of the tumor according to the tumor-node-metastasis staging system have 
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been demonstrated to significantly correlate with survival [7, 8] . In particular, a poorer outcome was observed for large residual tumors, supporting the development of non-crossresistant chemotherapy regimens to improve DFS and overall survival rates of patients with incomplete response to neoadjuvant chemotherapy [21] .
The presence of axillary lymph node metastasis is the bestestablished independent prognostic factor in women with newly diagnosed breast cancer. As reported in the most recent St. Gallen Consensus Conference, the number of involved axillary lymph nodes is pivotal in the risk evaluation [22] . Similar results, in terms of decreased survival associated with an increasing number of positive axillary nodes, were reported in patients pretreated with primary chemotherapy [23] .
Early studies suggested that the presence of PVI may provide additional prognostic information and that PVI is associated with a particularly unfavorable outcome among specific subgroups such as the node-negative population [24, 25] . In particular, the evaluation of the degree of PVI might properly identify patients at higher risk thus sparing unnecessary treatment in a large group of patients after surgery. Although emerging data on the clinical significance of PVI have prompted the introduction of this factor in the therapeutic algorithm of patients candidated to adjuvant treatment, PVI was uncommonly considered as a prognostic factor after PC. We previously showed that the presence of PVI after PC might identify patients with T4 disease at higher risk [26] . The results of the present study, where the degree of PVI was significantly correlated with DFS, further support a prognostic role for this factor.
Limited data are available on the relationship between HER2 expression and outcome after PC and HER was uncommonly taken into consideration in the development of models or nomograms. This might be explained by the small sample sizes, heterogeneity of examinations and methods and especially cutoffs used in the various studies. DFS was reported to be significantly worse for the population that overexpressed HER2 if compared with HER2-negative tumors in two large studies [27, 28] . In particular, in a retrospective analysis including 1731 patients, progressionfree survival rates were significantly worse for HER2-positive disease both in the cohort of patients HR positive and HR negative [27] . In the present study, we observed at the [22] . In particular, the degree of endocrine responsiveness according to the percentage of positive cells is considered as crucial in determining a probability of response to targeted treatments [22] . The value of the degree of endocrine responsiveness was, however, uncommonly taken into consideration in the therapeutic algorithm after preoperative therapy. In previously published studies, analyses were carried out based on a so-called 'receptor-negative grouping', which combines receptor-absent disease with that expressing low receptor levels, and 'receptor positive grouping' which combines all patients with tumors expressing ER and/or PgR in ‡10% of the cells. As reported in Table 3 , in the present study, the level of expression of ER was significantly correlated with the DFS of the patients and, therefore, the degree of expression of ER was introduced in the nomogram. According to these results, the degree of endocrine responsiveness evaluated quantitatively might contribute to a decision about postoperative treatment after PC.
Tumor proliferation fraction is an important predictor of prognosis. Ki-67 labeling index (LI) is a measure of tumor proliferation that has been correlated with outcome in several studies [29, 30] and in a recent meta-analysis conducted in >12 000 patients [31] . It has also been suggested that high Ki-67 LI may be predictive of responsiveness to neoadjuvant (primary) chemotherapy [32] , but it was not included in models or nomograms. More recently, a study focusing on 228 postmenopausal women with endocrine-responsive breast cancers treated within a neo-adjuvant endocrine therapy trial showed at the multivariable analysis of post-treatment tumor characteristics, that Ki-67 expression was independently associated with RFS [33] . The results of the present study indicate that measures of tumor cell proliferation such as Ki-67 expression could potentially identify patients who require further therapy (adjuvant chemotherapy as well as endocrine therapy) after PC in locally advanced breast cancer. The observed correlation between the degree of Ki-67 expression and the patients outcome implies the absolute necessity for reporting quantitative results from KI-67 LI staining with appropriate quality control.
In conclusion, in the present study, we developed a nomogram based upon expression of classical and newer pathologic characteristics of the primary tumor, which might accurately predict the risk of patients who failed to achieve a pCR after preoperative therapy. This nomogram may be useful when a postoperative 'tailored' algorithm should be developed in patients already submitted to preoperative treatment.
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